PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Immunovant, Inc. (IMVT)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US45258J1025

CUSIP

45258J102

Sector

Healthcare

IPO Date

Jun 21, 2019

Highlights

Market Cap

$4.10B

EPS (TTM)

-$2.21

Total Revenue (TTM)

$1.50M

Gross Profit (TTM)

$1.30M

EBITDA (TTM)

-$352.17M

Year Range

$24.61 - $45.58

Target Price

$48.93

Short %

19.66%

Short Ratio

14.98

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
IMVT vs. NARI IMVT vs. IRWD IMVT vs. MDGL IMVT vs. SMH IMVT vs. NDAQ IMVT vs. VOO IMVT vs. XMMO
Popular comparisons:
IMVT vs. NARI IMVT vs. IRWD IMVT vs. MDGL IMVT vs. SMH IMVT vs. NDAQ IMVT vs. VOO IMVT vs. XMMO

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Immunovant, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


100.00%150.00%200.00%250.00%JulyAugustSeptemberOctoberNovemberDecember
159.90%
101.01%
IMVT (Immunovant, Inc.)
Benchmark (^GSPC)

Returns By Period

Immunovant, Inc. had a return of -38.62% year-to-date (YTD) and -33.86% in the last 12 months.


IMVT

YTD

-38.62%

1M

-1.18%

6M

-5.34%

1Y

-33.86%

5Y*

10.14%

10Y*

N/A

^GSPC (Benchmark)

YTD

24.34%

1M

0.23%

6M

8.53%

1Y

24.95%

5Y*

13.01%

10Y*

11.06%

Monthly Returns

The table below presents the monthly returns of IMVT, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-13.58%-2.86%-8.65%-15.07%-7.47%3.98%10.11%6.30%-7.73%2.63%-3.62%-38.62%
20230.11%-1.69%-11.22%4.06%30.17%-9.71%20.35%-0.53%69.04%-13.91%18.40%7.67%137.35%
2022-17.96%-20.17%-1.25%-16.33%-8.03%-8.02%5.64%25.00%8.35%100.72%17.05%35.39%108.33%
2021-15.50%-59.57%1.65%-2.24%-3.32%-30.28%-1.04%-17.21%0.35%-7.48%-4.23%10.65%-81.55%
2020-0.50%-0.38%-1.05%19.24%38.25%-5.11%-7.15%50.20%3.62%23.96%12.77%-6.10%191.05%
2019-1.51%-0.10%1.12%1.21%1.40%2.85%51.87%59.50%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of IMVT is 20, meaning it’s performing worse than 80% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of IMVT is 2020
Overall Rank
The Sharpe Ratio Rank of IMVT is 1616
Sharpe Ratio Rank
The Sortino Ratio Rank of IMVT is 1818
Sortino Ratio Rank
The Omega Ratio Rank of IMVT is 2020
Omega Ratio Rank
The Calmar Ratio Rank of IMVT is 1717
Calmar Ratio Rank
The Martin Ratio Rank of IMVT is 3030
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Immunovant, Inc. (IMVT) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for IMVT, currently valued at -0.64, compared to the broader market-4.00-2.000.002.00-0.642.10
The chart of Sortino ratio for IMVT, currently valued at -0.74, compared to the broader market-4.00-2.000.002.004.00-0.742.80
The chart of Omega ratio for IMVT, currently valued at 0.92, compared to the broader market0.501.001.502.000.921.39
The chart of Calmar ratio for IMVT, currently valued at -0.54, compared to the broader market0.002.004.006.00-0.543.09
The chart of Martin ratio for IMVT, currently valued at -0.91, compared to the broader market-5.000.005.0010.0015.0020.0025.00-0.9113.49
IMVT
^GSPC

The current Immunovant, Inc. Sharpe ratio is -0.64. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Immunovant, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JulyAugustSeptemberOctoberNovemberDecember
-0.64
2.10
IMVT (Immunovant, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Immunovant, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-50.94%
-2.62%
IMVT (Immunovant, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Immunovant, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Immunovant, Inc. was 93.59%, occurring on Jun 16, 2022. The portfolio has not yet recovered.

The current Immunovant, Inc. drawdown is 50.94%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-93.59%Nov 18, 2020397Jun 16, 2022
-51.2%Jan 17, 202042Mar 18, 202018Apr 14, 202060
-20.5%Jun 24, 202027Jul 31, 202013Aug 19, 202040
-17.39%May 12, 20206May 19, 20204May 26, 202010
-13.21%Sep 17, 20205Sep 23, 202011Oct 8, 202016

Volatility

Volatility Chart

The current Immunovant, Inc. volatility is 13.15%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%JulyAugustSeptemberOctoberNovemberDecember
13.15%
3.79%
IMVT (Immunovant, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Immunovant, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Immunovant, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab